---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-006544"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:17:54.196708+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sirexatamab + chemo/bev shows 35% ORR in CRC (vs 23% control); gastric trial fails to advance to Phase 3

## Summary
- Part B DeFianCe (n=188): sirexatamab arm ORR 35% vs control 23%; DCR 86% vs 84%.
- Left-sided tumors ORR 38% (experimental) vs 25% (control); DKK1-high upper quartile ORR 48% vs 11%.
- PFS not yet mature; 82 patients still on study. Leap plans registrational Phase 3 in CRC subject to regulatory discussions.
- Part C DisTinGuish gastric: no clear positive signal; primary PFS endpoints will be negative; no Phase 3 plans for gastric.
- Gastric study showed high discordance between investigator and BICR; sirexatamab combo well-tolerated in both studies.

## SEC filing metadata
- accession: 0001104659-25-006544
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465925006544/0001104659-25-006544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465925006544/tm254560d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-006544
- JSON: https://secwatch.observer/filing/0001104659-25-006544.json
- Plain text: https://secwatch.observer/filing/0001104659-25-006544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.